“2025 has been transformational for Cassava. We have initiated a new program focused on TSC-related epilepsy, a rare disease for which patients urgently need more treatment options. Two encouraging animal model studies-one conducted at Yale and another with the TSC Alliance-support the exploration of simufilam as a novel, first-in-class approach to this disease,” said Rick Barry, President and Chief Executive Officer of Cassava.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SAVA:
- Cassava Sciences appoints Hulihan as Chief Medical Officer
- Cassava Sciences Announces Positive Preclinical Results
- Cassava reports preclinical study on simufilam for TSC-related epilepsy
- Cassava Sciences Reveals Promising Simufilam Preclinical Data
- Cassava Sciences presents poster at TSC 2025 on Simufilam